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Appendix of our article, available at NEJM.org). 
In addition to treatment group, histologic find-
ings emerged as an independent variable with re-
gard to both progression-free survival and overall 
survival. Extent of resection dropped out during 
the stepwise selection process for both. Conse-
quently, it is unlikely that either variable con-
founded the results.
Since radiation therapy can cause neurocogni-
tive decline, the appropriate time to initiate che-
motherapy plus radiotherapy or radiotherapy re-
mains controversial. Patients in the RTOG 9802 
trial were randomly assigned to begin radio-
therapy alone or chemotherapy plus radiotherapy 
within 4 weeks after surgery. The trial was not 
designed to address the question of timing of 
radiotherapy.
Neurocognitive end points from the trial were 
reported previously and showed no worsening of 
mean Mini–Mental State Examination scores in 
either treatment group up to 5 years after the 
initiation of treatment.1 These data do not ad-
dress less severe or more delayed neurocognitive 
decline.
In the randomized groups, 48% of the pa-
tients underwent biopsy only. Low-grade glio-
mas are characterized by low cellularity, which 
results in small amounts of available tissue. The 
two studies2,3 cited by Touat et al. enrolled pa-
tients with tumors with anaplastic oligodendrog-
lial elements rather than those with lower-grade 
oligodendroglial or astrocytic tumors (as were 
enrolled in the RTOG 9802 trial). In addition, 
when the trial began 18 years ago, institutional 
processes for collecting and submitting tumor 
tissue were less well developed than they are 
today. As a consequence, we had insufficient 
data for this report to address the effect of che-
motherapy plus radiotherapy in patients with 
IDH1/2 wild-type low-grade gliomas. Efforts are 
under way to obtain tissues to increase the pre-
dictive power of future correlative analyses from 
the RTOG 9802 trial.
We remind Knisely and Schulder that 63% of 
the patients with tumors that were tested had 
tumoral IDH1 R132H mutations. In this sub-
group, survival was longer among patients who 
received chemotherapy plus radiotherapy than 
among those who received radiotherapy alone 
(hazard ratio, 0.42; P = 0.02). There is clear evi-
dence to support treatment recommendations on 
the basis of current molecular classification for 
the majority of patients with low-grade glioma. 
Given the results of the RTOG 9402 and EORTC 
26951 trials,2,3 it is reasonable to expect a benefit 
with PCV in patients with either low-grade or 
anaplastic gliomas containing other tumoral 
IDH1/2 mutations and little reason to expect a 
benefit in those with IDH1/2 wild-type tumors.
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Management of Advanced Head and Neck Cancer
To the Editor: The PET-NECK randomized trial 
by Mehanna et al. (April 14 issue)1 compared sur-
veillance guided by positron-emission tomogra-
phy–computed tomography (PET-CT) with planned 
neck dissection after chemoradiotherapy in pa-
tients with head and neck squamous-cell carci-
noma (HNSCC) and stage N2 or N3 nodal metas-
tases. Patients who had a complete metabolic 
response but residual lymphadenopathy underwent 
neck dissection. A complete metabolic response 
on PET-CT in the presence of residual enlarged 
nodes has a high negative predictive value in oro-
pharyngeal carcinoma associated with human 
papillomavirus (HPV).2 Therefore, although these 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LEEDS on January 4, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 375;5 nejm.org August 4, 2016492
patients would have undergone neck dissection 
according to the trial protocol, Mehanna et al. 
suggest considering imaging follow-up in this 
patient subgroup.
A critical question is whether this approach 
can be extrapolated for non–HPV-related HNSCC 
with a complete metabolic response and residual 
adenopathy on PET-CT. Other studies have shown 
a high negative predictive value for a complete 
metabolic response on PET-CT in patients with 
residual nodal tissue and non–HPV-related can-
cers.3,4 Scoring systems for metabolic response 
assessment that are similar to those routinely 
used in patients with lymphoma have been de-
vised.4 Data regarding the safety and cost-effec-
tiveness of less intensive clinical follow-up in 
patients with HNSCC who have negative results 
on PET-CT after treatment have been reported.5 
Determining whether metabolically inactive re-
sidual lymph-node tissue can be safely observed 
for various HNSCC sites is an important priority.
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To the Editor: The PET-NECK trial by Mehanna 
et al. provides the first randomized trial evidence 
to support the routine use of PET-CT in lieu of 
planned neck dissection after a favorable response 
to definitive chemoradiation in patients with loco-
regionally advanced head and neck cancer. This 
trial builds on previous retrospective and obser-
vational data to show that surveillance PET-CT is 
associated with rates of locoregional control and 
overall survival that are similar to those associ-
ated with planned neck dissection for patients 
with stage N2 or N3 nodal metastases who have 
resolution of neck disease after chemoradiation. 
Unfortunately, the authors do not report the rates 
of residual pathologically positive lymph nodes at 
the time of neck dissection in either study group, 
nor do they report these rates stratified accord-
ing to tumor p16 status. This information, as well 
as factors associated with positive residual dis-
ease, would be important for clinicians in the 
interpretation of both the study results and 
equivocal findings on surveillance PET-CT in 
practice. The authors provide recommendations 
for treating patients with such equivocal find-
ings on the basis of tumor p16 status, but these 
recommendations could be fortified with data 
from the current study.
Caleb Dulaney, M.D. 
Lauren Kropp, M.D. 
James Bonner, M.D.
University of Alabama at Birmingham 
Birmingham, AL 
jabonner@ uabmc . edu
No potential conflict of interest relevant to this letter was re-
ported.
DOI: 10.1056/NEJMc1606211
The authors reply: We agree with Prestwich 
et al. that the question of whether metabolically 
inactive residual lymph-node tissue can be safely 
observed in various HNSCC sites is an important 
one. Currently available data for both HPV-posi-
tive and HPV-negative disease have been derived 
mainly from retrospective, relatively small, non-
randomized studies. When new data become 
available, the findings may spare a small number 
of additional patients from undergoing neck dis-
section.
We respectfully disagree with Dulaney et al. 
regarding the need for histopathological results 
on lymph-node status. It is widely accepted that 
there is no reliable way of identifying whether 
residual nodal tumor that is identified on histo-
logic analysis after chemoradiotherapy represents 
viable disease.1 Therefore, the use of such analy-
sis as an end point leads to an overestimation of 
positivity rates and has been one of the main 
weaknesses in the studies that have been pub-
lished to date. In our study, we sought to address 
this weakness by the use of clinically relevant 
primary and secondary outcomes — rates of over-
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all and disease-free survival. Finally, we reported 
data in our study for both HPV-positive and 
HPV-negative disease that showed the efficacy of 
active surveillance for both types of tumors.
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The Hospital Readmissions Reduction Program
To the Editor: Zuckerman et al. (April 21 issue)1 
found that hospital readmissions for conditions 
targeted for penalties fell by 3.7 percentage points, 
whereas stays in observation units rose by 2.1 
percentage points, yet they concluded that these 
two trends were not related because observation 
stays were rising even before the penalties were 
in place. Instead, the authors attribute continuous-
ly rising observation rates to hospitals’ confusion 
over the criteria used in audits of inpatient stays.
It seems unlikely that confusion over these 
regulations continued to increase for many years, 
leading hospitals to sacrifice billions by billing 
for observation stays rather than for more lucra-
tive admissions. More likely, hospital executives 
realized that, on balance, avoidance of readmis-
sion penalties by relabeling inpatient stays as 
“observation” was the most lucrative strategy.
The authors also overinterpret their statistics 
as showing no correlation between readmissions 
and observation stays. In fact, they, like previous 
analysts,2 found a weak positive correlation 
(P = 0.07) — indicating a 93% likelihood that 
falling readmissions and rising observations 
were related. Finally, their analysis ignores other 
potential gaming strategies — for example, up-
coding coexisting conditions to improve risk-
adjusted rates and shifting inpatient-type care to 
emergency departments.
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To the Editor: Zuckerman et al. examined chang-
es in readmission rates and the use of observa-
tion status after the 2012 initiation of financial 
penalties under the Medicare Hospital Readmis-
sions Reduction Program (HRRP). Their analysis 
was stratified according to HRRP targeted condi-
tions (acute myocardial infarction, heart failure, 
and pneumonia) versus all others. Gaining a bet-
ter understanding of readmissions is useful for 
a variety of Centers for Medicare and Medicaid 
Services programs, including the HRRP, the Hos-
pital Value-Based Purchasing Program, and the 
Bundled Payments for Care Improvement (BPCI) 
Initiative. Although some policymakers seek to 
expand readmission penalties to all hospitaliza-
tions, there is evidence to suggest that certain 
conditions might be prioritized over others.1 It 
may make sense to start with conditions covered 
by the BPCI initiative because the program cur-
rently has the largest number of conditions treat-
ed by a variety of medical and surgical special-
ties.2 Moreover, considerable effort was already 
undertaken to choose clinically meaningful and 
policy-relevant conditions for the BCPI program. 
Information on changes in readmission and ob-
servation rates (and the interaction between mea-
sures) for these conditions may provide valuable 
insight to both clinicians and policymakers.
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